Skip to main content
SpringerLink
Log in

Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: Insulin-like growth factor 1 (IGF-1) has mitogenic properties for breast cancer cell lines and has been proposed to be an important factor in breast carcinogenesis. We hypothesized that differences in IGF-1 or its binding proteins might increase susceptibility to breast cancer. This case-control study was designed to investigate whether patients with breast cancer have altered levels of either IGF-1 or its intermediary modulatory proteins, the IGF binding proteins (BP).

Methods: Serum was collected from 90 patients (63 with breast cancer and 27 with benign breast disease) after an overnight fast and before surgery. IGF-1, BP1, and BP3 levels were determined by immunoradiometric assays. In a subset of 66 patients, Western ligand blots were also performed for a semiquantitative measurement of functioning BP levels. A forward stepwise logistic regression model to adjust for other confounding variables (age, menopausal status, parity, age at menarche, use of oral contraceptives, history of breast biopsy, family history of breast cancer, hormone replacement therapy, and body-mass index) was used in the multivariate analysis.

Results: Serum IGF-1 levels were similar in cases and controls. However, levels of BP3 (p<0.001), BP4 (p<0.01), and BP1 (p<0.05) were significantly associated with risk of breast cancer. The level of BP3 was the most significant factor predictive of breast cancer. The odds ratio for breast cancer in women with BP3 levels >2066 ng/ml was 0.18 (95% CI, 0.05–0.55). Correspondingly, women with BP1 levels higher than 39 ng/ml had an odds ratio of 0.21 (95% CI, 0.07–0.68) for breast cancer. When considering only cancer patients (n=63), decreasing levels of BP4 (p<0.01) and increasing levels of BP1 (p<0.02) were significantly associated with progesterone receptor positivity (PR+) in the tumor. The odds ratio of PR+ in patients with BP1 levels higher than 34 ng/ml was 7.49 (95% CI, 1.5–37.4). Better grade of tumor (well and moderately differentiated) was observed in patients with higher levels of BP3 (p<0.03).

Conclusions: Distinct differences in BP profiles exist among patients with breast cancer and also among those with high-grade, hormonal receptor-negative tumors. These findings suggest that the bioavailability of IGF-1 as mediated by its binding proteins may participate in both breast carcinogenesis and selection of more aggressive breast carcinomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB. Secretion of an insulin-growth like factor I related protein by human breast cancer cells.Cancer Res 1986;46:4613–9.

    CAS  PubMed  Google Scholar 

  2. Karey KP, Sirbasku DA. Differential responsiveness and human breast cancer cell lines MCF-7 and T47D to growth factors and 17B estradiol.Cancer Res 1988;48:4083–92.

    CAS  PubMed  Google Scholar 

  3. Peyrat JP, Bonneterre J. Type I IGF receptor in human breast diseases.Breast Cancer Res Treat 1992;22:59–67.

    Article  CAS  PubMed  Google Scholar 

  4. Artega CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type 1 somatomedin receptor.Cancer Res 1989;49:6237–41.

    Google Scholar 

  5. Blum WF, Jenne EW, Reppin F, Kietzmann K, Ranke MB, Bierich JR. Insulin-like growth factor I (IGF-1) binding protein complex is a better mitogen than free IGF-1.Endocrinology 1989;125:766–72.

    CAS  PubMed  Google Scholar 

  6. De Mellow JSM, Baxter RC. Growth hormone dependent insulin-like growth (IGF) binding protein inhibits and potentiates IGF-1 stimulated DNA synthesis in human skin fibroblasts.Biochem Biophys Res Commun 1988;156:199–204.

    PubMed  Google Scholar 

  7. Clemmons DR, Elgin RG, Han VGM. Cultured fibroblast monolayers secrete a protein that alters the cellular binding of somatomedin C/insulin-like growth factor 1.J Clin Invest 1986;77:1548–56.

    CAS  PubMed  Google Scholar 

  8. Suikkari AM, Koivisto VA, Rutanen EM, Yki-Jarvinen H, Karonen SL, Seppala M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor binding protein.J Clin Endocrinol Metab 1988;66:266–72.

    CAS  PubMed  Google Scholar 

  9. Busby WH, Snyder DK, Clemmons DR. Radioimmunoassay of a 26,000-dalton plasma insulin-like growth factor binding protein: control by nutritional variables.J Clin Endocrinol Metab 1988;67:1225–30.

    CAS  PubMed  Google Scholar 

  10. Cotterill AM, Holly JMP, Wass JAH. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting.Clin Endocrinol 1993;39:357–62.

    CAS  Google Scholar 

  11. Clemmons DR, Snyder DK, Busby WH Jr. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects.J Clin Endocrinol Metab 1991;73:727–33.

    CAS  PubMed  Google Scholar 

  12. Brier BH, Gallaher BW, Gluckman PD. RIA for IGF-1: solutions to some potential problems and pitfalls.J Endocrinol 1991;128:347–57.

    Google Scholar 

  13. Lee KO, Ng SC, Lee PS, Bongso AT, Taylor EA, Lin TK, Ratnam SS. The effect of growth hormone therapy on men with severe idiopathic oligozoospermia.Eur J Endocrinol 1995;132:159–63.

    CAS  PubMed  Google Scholar 

  14. Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using Western blotting; using the method for titration of binding proteins and competitive binding studies.Ann Biochem 1986;154:138–43.

    Article  CAS  Google Scholar 

  15. Lee KO, Oh Y, Giudice LC, Cohen P, Peehl DM, Rosenfeld RG. Identification of insulin-like growth factor binding protein (IGFBP)-3 fragments, and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients.J Clin Endocrinol Metab 1994;79:1367–72.

    CAS  PubMed  Google Scholar 

  16. Wang HS, Lee JD, Soong YK. Serum levels of serum insulin-like growth factor 1 and serum insulin-like growth factor-binding proteins -1 and -3 in women with regular menstrual cycles.Fertil Steril 1995;63:1204–9.

    CAS  PubMed  Google Scholar 

  17. Clemmons DR, Underwood LE, Dickerson RN, Brown RO, Hak LJ, MacPhee RD, Heizer WD. Use of plasma somatomedin-C/serum insulin-like growth factor 1 measurements to monitor the response to nutritional repletion in malnourished patients.Am J Clin Nutr 1985;41:191–8.

    CAS  PubMed  Google Scholar 

  18. Unterman TG, Vazquez RM, Slas AJ, Martyn PA, Phillips LS. Nutrition and somatomedin XIII. Usefulness of somatomedin-C in nutritional assessment.Am J Med 1985;78:228–34.

    Article  CAS  PubMed  Google Scholar 

  19. Favoni RE, de Cupis A, Perotta A, Sforzini S, Amoroso D, Pensa F, Miglietta L. Insulin-like growth factor 1 (IGF-1) and IGF-binding proteins blood serum levels in women with early and late stage breast cancer; mutual relationship and possible correlation with patients' hormone status.J Cancer Res Clin Oncol 1995;121:674–82.

    Article  CAS  PubMed  Google Scholar 

  20. Bruning PF, Van Doorn J, Bonfrer JMG, Van Noord PAH, Korse CM, Linders TC, Hart AAM. Insulin-like growth factor binding protein 3 is decreased in early operable pre-menopausal breast cancer.Int J Cancer 1995;62:266–70.

    CAS  PubMed  Google Scholar 

  21. Purohit A, Chapman O, Duncan L, Reed MJ. Modulation of oestrone sulphatase activity in breast cancer cell lines by growth factors.J Steroid Biochem Mol Biol 1992;41:563–66.

    Article  CAS  PubMed  Google Scholar 

  22. Lueprasitsakul P, Latour D, Longcope C. Aromatase activity in human adipose-tissue: stromal effects of growth factors.Steroids 1990;55:540–4.

    Article  CAS  PubMed  Google Scholar 

  23. Colletti RB, Roberts JD, Devlin JT, Copeland KC. Effects of tamoxifen on plasma insulin-like growth factor 1 in patients with breast cancer.Cancer Res 1989;49:1882–4.

    CAS  PubMed  Google Scholar 

  24. Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media.Cancer Res 1993;53:5193–8.

    CAS  PubMed  Google Scholar 

  25. Adamo ML, Shao Z, Lanau F, et al. Insulin-like growth factor 1 and retinoic acid modulation of IGF-binding proteins:IGFBP-2,-3,-4 gene expression and protein secretion in a breast cancer cell line.Endocrinology 1992;131:1858–66.

    Article  CAS  PubMed  Google Scholar 

  26. Oh Y, Mullers HL, Ng L, Rosenfeld RG. Transforming growth factor-b-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action.J Biol Chem 1995;270:13589–92.

    CAS  PubMed  Google Scholar 

  27. Oh Y, Mullers HL, Ng L, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells.J Biol Chem 1993;268:26045–8.

    CAS  PubMed  Google Scholar 

  28. Holly JMP. The physiological role of IGFBP-1.Acta Endocrinol 1991;124:55–62.

    PubMed  Google Scholar 

  29. Binoux M, Hossenlopp P. Insulin-like growth and IGF binding proteins; comparison of human serum and lymph.J Clin Endocrinol Metab 1988;67:509–14.

    CAS  PubMed  Google Scholar 

  30. Carlsson-Skwirut C, Lake M, Hartmanis M, Hall K, Sara VR. A comparison of the biological activity of the recombinant intact and truncated insulin-like growth factor 1 (IGF-1).Biochem Biophys Acta 1989;1011:192–7.

    CAS  PubMed  Google Scholar 

  31. Elgin RG, Busby WH Jr, Clemmons DR. An insulin-like growth factor binding protein enhances the biologic response to IGF-1.Proc Natl Acad Sci USA 1987;84:3254–8.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Laboratory of Surgical Oncology and Metabolism, Department of Surgery, National University of Singapore, Singapore

    Eng-Hen Ng MD, Chen-Yang Ji MD, Valerie Lin PhD & Khee-Chee Soo MD

  2. Department of Pathology, Singapore General Hospital, National University of Singapore, Singapore

    Puay-Hoon Tan MD

  3. Department of Medicine, National University of Singapore, Singapore

    Kok-Onn Lee MD

Authors
  1. Eng-Hen Ng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chen-Yang Ji MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Puay-Hoon Tan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valerie Lin PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Khee-Chee Soo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kok-Onn Lee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ng, EH., Ji, CY., Tan, PH. et al. Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients. Annals of Surgical Oncology 5, 194–201 (1998). https://doi.org/10.1007/BF02303854

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02303854

Key Words

Search

Navigation